Antiviral Therapy Trial for Parkinson's Disease

V2, Crosslink

🧫

Antiviral Therapy Trial for Parkinson's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-antivira

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Antiviral Therapy Trial for Parkinson's Disease ## Background and Rationale This clinical trial tests the viral trigger hypothesis in Parkinson's disease by investigating whether herpes simplex virus (HSV) reactivation contributes to neurodegeneration and whether antiviral therapy can modify disease progression. Emerging evidence suggests that HSV-1 can infect dopaminergic neurons and trigger α-synuclein aggregation through inflammatory cascades and cellular stress responses. The virus may est

METHODOLOGY NOTES

**Phase 1: Screening and Enrollment (Weeks 1-4)** • Screen 400 potential participants aged 50-75 with early-stage PD (Hoehn & Yahr stages 1-2) • Confirm PD diagnosis using Movement Disorder Society criteria and DaTscan imaging • Collect baseline blood samples for HSV-1 IgG seropositivity testing using ELISA • Exclude patients with active HSV lesions, immunocompromised status, or advanced PD • Obtain written informed consent and randomize 200 HSV-1 seropositive participants **Phase 2: Baseline Assessment (Weeks 5-8)** • Administer comprehensive neurological assessments: MDS-UPDRS Parts I-IV, MoCA, PDQ-39 • Collect CSF samples via lumbar puncture for HSV-1 DNA quantification using qPCR • Measure plasma HSV-1 DNA levels and inflammatory markers (TNF-α, IL-1β, IL-6) • Perform DaTscan imaging to assess dopaminergic neuron integrity • Document all concurrent medications and establish medication diary protocols **Phase 3: Randomized Treatment (Weeks 9-60)** • Randomize participants 1:1 to v

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.903520Z'}
summary	# Antiviral Therapy Trial for Parkinson's Disease ## Background and Rationale This clinical trial tests the viral trigger hypothesis in Parkinson's disease by investigating whether herpes simplex viru
entities	{'genes': ['HSV'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Change in dopamine transporter binding measured by DaTscan SPECT imaging from baseline to 18 months in antiviral-treated versus placebo groups. Secondary outcomes include motor symptom progression (MD
methodology_notes	Phase 1: Screening and Enrollment (Weeks 1-4) • Screen 400 potential participants aged 50-75 with early-stage PD (Hoehn & Yahr stages 1-2) • Confirm PD diagnosis using Movement Disorder Society cr
replication_status	conflicting
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.903525', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

688

Outgoing

659

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Antiviral Therapy Trial for Parkinson's Disease

derives from (16)

supports (5)

💬 Discussion